Respiratory Disease Testing Market
Get a free sample of this report
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Request Sectional Data
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Respiratory Disease Testing Market size was worth USD 14 billion in 2022 and is anticipated to exhibit 6.5% CAGR from 2023-2032. Rising burden of pulmonary and hospital-acquired infections is likely to favor market dynamics.
The growing number of government-led initiatives, specifically in the developed and developing regions will complement the market expansion. Several government bodies are coming up with awareness programs for educating the mass population about various respiratory disorders and their prevention. To illustrate, the National Heart, Lung, and Blood Institute introduced the COPD Learn More Breathe Better (LMBB) campaign for instigating higher awareness along with educating the public regarding COPD (chronic obstructive pulmonary diseases). The campaign is also directed at offering early detection and treatment to individuals affected by various lung diseases.
| Report Attribute | Details |
|---|---|
| Base Year: | 2022 |
| Respiratory Disease Testing Market size in 2022: | USD 14 Billion |
| Forecast Period: | 2023 to 2032 |
| Forecast Period 2023 - 2032 CAGR: | 6.5 |
| 2023 Value Projection: | USD 26 Billion |
| Historical Data for: | 2018 to 2022 |
| No of Pages: | 446 |
| Tables, Charts & Figures: | 202 |
| Segments Covered: | Test Type, Application, End use, and Region |
| Growth Drivers: |
|
| Pitfalls Challenges: |
|
The escalating costs associated with respiratory disease testing devices may negatively influence the respiratory disease testing market development. To that end, the increasing number of geriatric individuals prone to chronic respiratory infections in some developing countries are refraining from deploying these diagnostic techniques. The presence of financial constraints especially in the economically backward countries and lower-income groups will further hamper the business landscape.
Based on test type, the respiratory disease testing market size from in vitro diagnostics tests is anticipated to showcase more than 6% CAGR from 2023-2032. In vitro diagnostics (IVD) respiratory tests or laboratory-based tests are extensively adopted as they render multiple advantages for the diagnosis and treatment of respiratory conditions. Some of these include delivering both non-invasive as well as customizable accurate and rapid results, while ensuring that healthcare providers are offering effective, affordable and personalized care. IVD respiratory tests also help to analyse the samples of bodily fluids, including blood, sputum, or urine for detecting and diagnosing the respiratory conditions.
Respiratory disease testing market share from the hospitals end-use segment will exceed USD 10 billion by 2032 due to the strong availability of advanced medical equipment and treatment options. Hospitals are increasingly favoured by patients as they offer better interaction of healthcare professionals on account of ease of accessibility. The growing influx of technologically advanced devices to treat the rising respiratory ailments across the hospital settings in the developed as well as developing countries will anchor the market development.
North America respiratory disease testing market size is anticipated to strike 6.4% CAGR from 2023-2032. The growth can be attributed to the presence of well-developed healthcare infrastructure in the region. The robust presence of a large number of business players has spurred the introduction of diverse product offerings. The rising burden of respiratory diseases will further anchor the product adoption. As per CDC (Centers for Disease Control and Prevention), nearly 4.6% of adults were diagnosed with emphysema, COPD, or chronic bronchitis in the U.S. in 2021.
Some of the leading players in the respiratory disease testing market include:
By Test Type
By Application
By End-use
The above information is provided for the following regions and countries:
Abbott, Becton, Dickinson, and Company, Koninklijke Philips N.V., ResMed, VYAIRE MEDICAL, INC., Fischer & Paykel, Medtronic, BioMerieux SA, Cosmed, Seegene Inc., SDI Diagnostics, and Siemens Healthineers are the major market participants.
The respiratory disease testing market in North America will record 6.4% CAGR from 2023-2032 on account of the strong presence of well-developed healthcare infrastructure in the region.
Global market for respiratory disease testing reached USD 14 billion in 2022 and will exhibit 6.5% CAGR from 2023-2032 due to the growing number of government-led initiatives.
In vitro diagnostics tests will showcase more than 6% CAGR from 2023-2032 owing to their multiple advantages in the diagnosis and treatment of respiratory conditions.